BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC lifted its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 0.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,288,778 shares of the biotechnology company's stock after purchasing an additional 28,728 shares during the period. Geode Capital Management LLC owned 1.73% of BioMarin Pharmaceutical worth $215,784,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the stock. TD Private Client Wealth LLC raised its holdings in shares of BioMarin Pharmaceutical by 57.4% during the 3rd quarter. TD Private Client Wealth LLC now owns 510 shares of the biotechnology company's stock worth $36,000 after acquiring an additional 186 shares during the period. SBI Securities Co. Ltd. purchased a new position in BioMarin Pharmaceutical during the fourth quarter worth about $36,000. CIBC Private Wealth Group LLC boosted its holdings in BioMarin Pharmaceutical by 64.2% in the 4th quarter. CIBC Private Wealth Group LLC now owns 596 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 233 shares during the last quarter. Smartleaf Asset Management LLC grew its stake in shares of BioMarin Pharmaceutical by 111.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 885 shares of the biotechnology company's stock valued at $58,000 after buying an additional 466 shares during the period. Finally, UMB Bank n.a. increased its holdings in shares of BioMarin Pharmaceutical by 260.1% during the 4th quarter. UMB Bank n.a. now owns 1,019 shares of the biotechnology company's stock worth $67,000 after buying an additional 736 shares during the last quarter. 98.71% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Insider Buying and Selling

In other news, CAO Erin Burkhart sold 1,344 shares of the company's stock in a transaction on Monday, February 24th. The stock was sold at an average price of $68.38, for a total value of $91,902.72. Following the completion of the sale, the chief accounting officer now owns 13,105 shares in the company, valued at $896,119.90. This represents a 9.30 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 1.85% of the stock is owned by corporate insiders.

BioMarin Pharmaceutical Stock Performance

BMRN traded down $4.08 during trading hours on Thursday, hitting $55.35. The company's stock had a trading volume of 601,233 shares, compared to its average volume of 1,879,874. The company has a 50-day simple moving average of $67.44 and a 200 day simple moving average of $66.80. The company has a current ratio of 5.33, a quick ratio of 2.62 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $10.56 billion, a PE ratio of 25.16, a PEG ratio of 0.61 and a beta of 0.30. BioMarin Pharmaceutical Inc. has a fifty-two week low of $52.93 and a fifty-two week high of $94.85.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last issued its quarterly earnings data on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share for the quarter, beating analysts' consensus estimates of $0.54 by $0.18. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%. The business had revenue of $747.31 million for the quarter, compared to analysts' expectations of $711.05 million. As a group, sell-side analysts expect that BioMarin Pharmaceutical Inc. will post 3.15 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on BMRN shares. Cantor Fitzgerald reissued an "overweight" rating and set a $90.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. Oppenheimer raised shares of BioMarin Pharmaceutical from a "market perform" rating to an "outperform" rating and set a $98.00 target price on the stock in a research report on Monday, February 24th. StockNews.com upgraded shares of BioMarin Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research report on Wednesday. Scotiabank lifted their target price on shares of BioMarin Pharmaceutical from $78.00 to $80.00 and gave the company a "sector perform" rating in a report on Thursday, February 20th. Finally, Royal Bank of Canada reaffirmed a "sector perform" rating and set a $70.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. Seven research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $94.00.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.